South Korean drug developer Samsung Bioepis is closer to bringing another biosimilar to the European market – this time referencing the breast and gastric cancer drug Herceptin (trastuzumab).
The company, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), has had its Marketing Authorization Application (MAA) accepted by the European Medicines Agency (EMA) for the SB3 biosimilar candidate referencing the branded biologic sold by Genentech, a subsidiary of Swiss drug giant, Roche (VTX: ROG).
"If approved, we hope our affordable, high-quality medicine will help realize the promise of biosimilars for breast cancer patients across Europe"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze